Literature DB >> 9255565

Biomarkers of gene expression: growth factors and oncoproteins.

P W Brandt-Rauf1.   

Abstract

This article reviews the literature on the application of methods for the detection of growth factors, oncogene proteins, and tumor-suppressor gene proteins in the blood of humans with cancer or who are at risk for the development of cancer. The research summarized here suggests that many of these biomarker assays can be used to distinguish between diseased and nondiseased states and in some instances may be able to predict susceptibility for future disease. Thus, these biomarkers could be valuable tools for monitoring at-risk populations for purposes of disease prevention and control.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9255565      PMCID: PMC1470051          DOI: 10.1289/ehp.97105s4807

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  100 in total

1.  Serum insulin-like growth factor-I levels in patients with small cell lung cancer.

Authors:  V M Macaulay; J D Teale; M J Everard; G P Joshi; J L Millar; I E Smith
Journal:  Eur J Cancer Clin Oncol       Date:  1988-07

2.  A novel tumour marker related to the c-myc oncogene product.

Authors:  S Chan; H Gabra; F Hill; G Evan; K Sikora
Journal:  Mol Cell Probes       Date:  1987-03       Impact factor: 2.365

3.  Serum insulin-like growth factor II in chronic liver disease.

Authors:  T Hayakawa; T Kondo; T Shibata; M Kitagawa; H Ono; Y Sakai; K Kato; N Katada; Y Sugimoto; M Takeichi
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

4.  Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer.

Authors:  M S Anscher; W P Peters; H Reisenbichler; W P Petros; R L Jirtle
Journal:  N Engl J Med       Date:  1993-06-03       Impact factor: 91.245

5.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer.

Authors:  L V Crawford; D C Pim; R D Bulbrook
Journal:  Int J Cancer       Date:  1982-10-15       Impact factor: 7.396

6.  Anti-peptide antibodies detect oncogene-related proteins in urine.

Authors:  H L Niman; A M Thompson; A Yu; M Markman; J J Willems; K R Herwig; N A Habib; C B Wood; R A Houghten; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

7.  Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma.

Authors:  C Caron de Fromentel; F May-Levin; H Mouriesse; J Lemerle; K Chandrasekaran; P May
Journal:  Int J Cancer       Date:  1987-02-15       Impact factor: 7.396

8.  Serum screening for oncogene proteins in workers exposed to PCBs.

Authors:  P W Brandt-Rauf; H L Niman
Journal:  Br J Ind Med       Date:  1988-10

9.  Detection of circulating antibodies against c-myc protein in cancer patient sera.

Authors:  K Ben-Mahrez; D Thierry; I Sorokine; A Danna-Muller; M Kohiyama
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

10.  Construction of immunoradiometric assay for circulating c-erbB-2 protooncogene product in advanced breast cancer patients.

Authors:  M Hosono; T Saga; H Sakahara; H Kobayashi; M Shirato; K Endo; T Yamamoto; T Akiyama; K Toyoshima; J Konishi
Journal:  Jpn J Cancer Res       Date:  1993-02
View more
  1 in total

Review 1.  12th meeting of the Scientific Group on Methodologies for the Safety Evaluation of Chemicals: susceptibility to environmental hazards.

Authors:  J C Barrett; H Vainio; D Peakall; B D Goldstein
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.